Senolytic Research Library

Core fisetin and senolytic references

• Yousefzadeh et al. (2018), fisetin as a senotherapeutic
• Zhu et al. (2017), senolytic activity is cell-type dependent
• ClinicalTrials.gov NCT06431932, fisetin pharmacokinetic pilot study
• Phase II fisetin study protocol in postmenopausal breast-cancer survivors

We intentionally distinguish cell/animal evidence from human clinical evidence. That distinction is central to responsible longevity content.

Research references

Why primary research matters

Primary studies and high-quality reviews are more useful than repeating claims across supplement blogs. The research library exists to show the evidence behind the commercial guides.

How evidence is prioritized

Human randomized trials and systematic reviews carry more weight for outcome claims than cell or animal research. Preclinical evidence remains useful for mechanism and hypothesis generation.

How trials are interpreted

Participant characteristics, sample size, dose, duration, comparator, primary outcomes, adverse events, and funding all affect what can reasonably be concluded.

Ingredient versus finished-product evidence

A commercial product should not automatically inherit every finding associated with a named ingredient. Formula, dose, source, purity, and co-ingredients can matter.

Null findings matter

Negative or null studies should not be hidden because they weaken a marketing story. They help define the actual boundary of the evidence.

Updates

New trials can change the strength of a conclusion. Research pages should remain revisable.

Funding and conflicts

Industry funding is relevant context but should not be used as a shortcut for either accepting or dismissing a study.

How readers should use the library

The research library is most useful for identifying what is known, what remains uncertain, and where commercial claims extend beyond current human evidence.

Update trigger 1

For Senolytic Research Library, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.

Update trigger 2

For Senolytic Research Library, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.

Update trigger 3

For Senolytic Research Library, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.

Update trigger 4

For Senolytic Research Library, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.

Update trigger 5

For Senolytic Research Library, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.

Update trigger 6

For Senolytic Research Library, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.

Update trigger 7

For Senolytic Research Library, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.

Update trigger 8

For Senolytic Research Library, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.

Update trigger 9

For Senolytic Research Library, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.

Update trigger 10

For Senolytic Research Library, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.

Update trigger 11

For Senolytic Research Library, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.

Update trigger 12

For Senolytic Research Library, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.

Update trigger 13

For Senolytic Research Library, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.